Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Institut De Recherches Internationales Servier IRIS
Sponsor

Institut De Recherches Internationales Servier IRIS

France 22 Route 128, 91190, France

About the sponsor

Acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are prominent areas of interest, with additional attention to relapsed and refractory disease and mutation-defined blood cancers.

  • IDH1-mutated AML
  • IDH2-mutated AML
  • MDS/AML
  • CMML

Research activity also includes treatment settings for newly diagnosed and previously treated hematologic malignancies.

About Specializations

Institut De Recherches Internationales Servier IRIS runs clinical trials in conditions such as Acute myeloid leukaemia, Neoplasm malignant, Myelodysplastic syndrome, Chronic myelomonocytic leukaemia, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

20 clinical trials

Neoplasm malignant

Recruiting

A study of S-241656 and a drug combination in patients with certain types of cancer involving KRAS, BRAF, or other RAS/MAPK mutations

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Epileptic encephalopathy

Recruiting

Study of intrathecal S230815 to evaluate safety and effectiveness in children with KCNT1-related Developmental and Epileptic Encephalopathy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:S230815-2
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Myelodysplastic syndrome

Recruiting

Study on Ivosidenib and Azacitidine for Adults with Myelodysplastic Syndromes and IDH1 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Chondrosarcoma

Recruiting

Study of ivosidenib in adults with advanced or metastatic chondrosarcoma with IDH1 mutation who are untreated or have had one prior treatment

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ivosidenib
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Acute myeloid leukaemia+2

Not yet recruiting

Safety and tolerability study of S-241656 with posaconazole in patients with AML, MDS/AML or CMML

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Posaconazole
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Acute lymphocytic leukaemia

Not yet recruiting

Long‑term safety study of S68587 (allogeneic CD19 CAR T‑cells with TRAC and CD52 disruption) in patients with advanced lymphoid leukemia

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Cholangiocarcinoma

Not yet recruiting

Study of Ivosidenib, Durvalumab, and Gemcitabine/Cisplatin for Patients with Advanced Cholangiocarcinoma with IDH1 Mutation

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Non-small cell lung cancer+1

Not yet recruiting

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Hereditary ataxia

Not recruiting

Safety and tolerability of intrathecal S233107 in participants with spinocerebellar ataxia type 3: a Phase 1b/2a first‑in‑human randomized study

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Type 2 diabetes mellitus

Not recruiting

Single‑dose Bioavailability of Gliclazide Modified‑Release Tablets in Healthy Volunteers (Type 2 Diabetes)

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · Healthy volunteers
  • Substances:Gliclazide
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Neoplasm malignant

Not recruiting

Study of S095035 and TNG462 in adults with advanced or metastatic solid tumors with MTAP deletion

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:S095035
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Glioma

Not recruiting

Study on the Safety and Effectiveness of Vorasidenib and Temozolomide for Patients with IDH1 or IDH2 Mutant Glioma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Temozolomide
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.